COVID-19

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Ascension St. Thomas, Tristar Health, Meharry Medical College/Nashville General Hospital, Vanderbilt Health issue joint statement on COVID-19

The number of active COVID-19 cases in Tennessee is rising. In the 13 counties that comprise the Nashville Metropolitan Area, new cases have increased 50% over the last 2 weeks. We strongly urge everyone in Middle Tennessee, and all Tennesseans, to remain vigilant in their efforts to limit the spread of the virus by wearing masks, washing hands and staying socially distant — including not participating in large gatherings.

Clinical trial to test HIV drugs to treat COVID-19

Vanderbilt University Medical Center, in collaboration with the University of Colorado and Beth Israel Deaconess Medical Center in Boston, is leading one of the first “telemedicine” clinical trials to test a potential treatment for COVID-19.

Possible COVID-19 “decoy”

It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.

Posing with the award presented by the Tennessee Hospital Association are (front row, from left) Molly Knostman, PharmD, MHA, C. Wright Pinson, MBA, MD, Patty Wright, MD, Mark Sullivan, PharmD (back row, from left) Halden Van Cleave, PharmD, MS, Deidra Dickerson, PharmD, Garrett Crothers, PharmD, Kevin Scharfman, PharmD, Eric Patton and Ryan Schell, PharmD.

THA honors VUMC efforts in remdesivir distribution

A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.

COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

1 19 20 21 22 23 39